
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:Poor chemotherapy response remains a major treatment challenge for high-grade serous ovarian cancer (HGSC). Cancer stem cells are the major contributors to relapse and treatment failure as they can survive conventional therapy. Our objectives were to characterise stemness features in primary patient-derived cell lines, correlate stemness markers with clinical outcome and test the response of our cells to both conventional and exploratory drugs. Tissue and ascites samples, treatment-naive and/or after neoadjuvant chemotherapy, were prospectively collected. Primary cancer cells, cultured under conditions favouring either adherent or spheroid growth, were tested for stemness markers; the same markers were analysed in tissue and correlated with chemotherapy response and survival. Drug sensitivity and resistance testing was performed with 306 oncology compounds. Spheroid growth condition HGSC cells showed increased stemness marker expression (including aldehyde dehydrogenase isoform I; ALDH1A1) as compared with adherent growth condition cells, and increased resistance to platinum and taxane. A set of eight stemness markers separated treatment-naive tumours into two clusters and identified a distinct subgroup of HGSC with enriched stemness features. Expression of ALDH1A1, but not most other stemness markers, was increased after neoadjuvant chemotherapy and its expression in treatment-naive tumours correlated with chemoresistance and reduced survival. In drug sensitivity and resistance testing, five compounds, including two PI3K-mTOR inhibitors, demonstrated significant activity in both cell culture conditions. Thirteen compounds, including EGFR, PI3K-mTOR and aurora kinase inhibitors, were more toxic to spheroid cells than adherent cells. Our results identify stemness markers in HGSC that are associated with a decreased response to conventional chemotherapy and reduced survival if expressed by treatment-naive tumours. EGFR, mTOR-PI3K and aurora kinase inhibitors are candidates for targeting this cell population. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
展开更多
最新影响因子:9.883 | 期刊ISSN:0022-3417 | CiteScore:5.86 |
出版周期:Monthly | 是否OA:YES | 出版年份:1969 |
期刊官方网址:http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9896
自引率:2.20% | 研究方向:医学-病理学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The main interests of the Journal of Pathology lie in the pathophysiological and pathogenetic mechanisms of human disease and in the application of such knowledge to diagnosis and prognosis. In determining content the primary considerations are excellence relevance and novelty. The Journal welcomes investigative studies on human tissues experimental studies in vitro and in vivo and investigations based on animal models with a clear relevance to human disease including transgenic systems. Methodological improvements in investigative and diagnostic pathology are also of interest. Correlative studies of pathological data and clinical outcomes are encouraged but purely descriptive papers on diagnostic pathology are not considered central to the Journal's purpose. In general studies which appropriately employ multiple investigative techniques are preferred over those which rely on a single methodology. Illustrations must be of the highest quality to be acceptable for publication. As well as original research papers the Journal seeks to provide rapid publication in a variety of other formats including editorials review articles and other features both contributed and solicited. Papers covering significant developments in teaching methods and in the practice of pathology may be acceptable if they are of international scope and relevance. Correspondence from readers will be published if it is of general interest. In summary the Journal aims to serve as a bridge between basic biomedical science and clinical medicine. As a Journal of the Pathological Society of Great Britain and Ireland it seeks to reflect the broad scientific interests of the Society's membership but its ethos authorship content and purpose are those expected of a leading publication in the international scientific literature.
《病理学杂志》的主要兴趣在于人类疾病的病理生理和发病机制,以及这些知识在诊断和预后中的应用。在确定内容时,主要考虑的是卓越的相关性和新颖性。该杂志欢迎对人体组织的研究,体外和体内的实验研究,以及基于与人类疾病(包括转基因系统)有明确关联的动物模型的研究。研究性和诊断性病理学的方法改进也很有趣。鼓励对病理学数据和临床结果进行相关研究,但关于诊断病理学的纯描述性论文并不被认为是该杂志的核心目的。一般来说,适当采用多种调查方法的研究比依赖单一方法的研究更为可取。插图必须具有最高质量,才能出版。除了最初的研究论文,该杂志还寻求以各种其他形式提供快速出版,包括社论评论文章和其他既有贡献又有索取的特色。如果论文涉及到教学方法和病理学实践的重大发展,并且具有国际范围和相关性,则可以接受。如果读者的信件符合一般利益,将予以公布。总之,该杂志的目标是成为基础生物医学科学和临床医学之间的桥梁。作为大不列颠和爱尔兰病理学会的一本杂志,它试图反映该学会成员的广泛科学利益,但它的精神、作者内容和目的是国际科学文献的主要出版物。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
PATHOLOGY (病理学) 2区 ONCOLOGY (肿瘤学) 2区 |
32/223 5/79 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
142 | 137 | 5 |
引文计数(2018)
文献(2015-2017)
2919次引用
498篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Pathology and Forensic Medicine
|
#4/185
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
14年经验沉淀,实体公司
运营
liting7111
研究方向:医药科学 肿瘤学 肿瘤发生
审稿时间: 2个月内
liting7111
研究方向:kidney tumor
接受率: 比较困难(25%命中)
liting7111
接受率: 比较困难(25%命中)
影响因子:13.029
ISSN:1522-8517
研究方向:医学-临床神经学
影响因子:4.506
ISSN:0167-594X
研究方向:医学-临床神经学
影响因子:7.723
ISSN:2162-402X
研究方向:ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
影响因子:4.912
ISSN:1524-9557
研究方向:医学-免疫学
影响因子:12.02
ISSN:2326-6066
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:3.698
ISSN:1750-9378
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:6.63
ISSN:0340-7004
研究方向:医学-免疫学
影响因子:3.077
ISSN:1534-7354
研究方向:医学-全科医学与补充医学
影响因子:0
ISSN:1868-8497
研究方向:ONCOLOGY-ENDOCRINOLOGY & METABOLISM
JOURNAL OF PATHOLOGY 投稿经验
(由下方点评分析获得,3人参与,10196人阅读)